[go: up one dir, main page]

WO2001027261A3 - Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino - Google Patents

Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino Download PDF

Info

Publication number
WO2001027261A3
WO2001027261A3 PCT/DK2000/000580 DK0000580W WO0127261A3 WO 2001027261 A3 WO2001027261 A3 WO 2001027261A3 DK 0000580 W DK0000580 W DK 0000580W WO 0127261 A3 WO0127261 A3 WO 0127261A3
Authority
WO
WIPO (PCT)
Prior art keywords
pna
nucleic acid
peptides
lna
morpholino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2000/000580
Other languages
French (fr)
Other versions
WO2001027261A2 (en
Inventor
Peter E Nielsen
Liam Good
Henrik Frydenlund Hansen
Frederik Beck
Leila Malik
Carsten Schou
Margit Wissenbach
Birgit Kjaeldgaard Giwercman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pantheco AS
Original Assignee
Pantheco AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK199801467A external-priority patent/DK173006B1/en
Priority to BR0014756-7A priority Critical patent/BR0014756A/en
Priority to IL14909500A priority patent/IL149095A0/en
Priority to EP00967618A priority patent/EP1220902A2/en
Priority to HU0203465A priority patent/HUP0203465A2/en
Priority to AU77730/00A priority patent/AU7773000A/en
Application filed by Pantheco AS filed Critical Pantheco AS
Priority to CA002388991A priority patent/CA2388991A1/en
Priority to JP2001530466A priority patent/JP2003511466A/en
Publication of WO2001027261A2 publication Critical patent/WO2001027261A2/en
Publication of WO2001027261A3 publication Critical patent/WO2001027261A3/en
Priority to NO20021711A priority patent/NO20021711L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61L2103/05—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns novel drugs for use in combating infectious micro-organisms, in particular bacteria. More particularly the invention concerns peptide nucleic acid (PNA) sequences, which are modified by conjugating cationic peptides to the PNA in order to obtain novel PNA molecules with enhanced anti-infective properties.
PCT/DK2000/000580 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino Ceased WO2001027261A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001530466A JP2003511466A (en) 1998-11-11 2000-10-13 Modified PNA molecule
IL14909500A IL149095A0 (en) 1998-11-11 2000-10-13 Conjugates between a peptide and a nucleic acid analog, such as pna, lna or a morpholino
EP00967618A EP1220902A2 (en) 1998-11-11 2000-10-13 Conjugates between a peptide and a nucleic acid analog, such as a pna, lna or a morpholino
HU0203465A HUP0203465A2 (en) 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
AU77730/00A AU7773000A (en) 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or amorpholino
BR0014756-7A BR0014756A (en) 1998-11-11 2000-10-13 Conjugates between a peptide and a nucleic acid analog, such as a pna, an lna or a morpholino
CA002388991A CA2388991A1 (en) 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
NO20021711A NO20021711L (en) 1998-11-11 2002-04-11 Conjugates of a peptide and a nucleic acid analog, such as a PNA, LNA or a morpholino

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
DK199801467A DK173006B1 (en) 1998-11-11 1998-11-11 Method and plant for producing wall material for use in the manufacture of compensators, in particular for flue gas channels, as well as compensator material and compensator produced by the method
DKPA199901471 1999-10-13
DKPA199901471 1999-10-13
DKPA199901467 1999-10-13
US15968499P 1999-10-15 1999-10-15
US15967999P 1999-10-15 1999-10-15
US60/159,679 1999-10-15
US60/159,684 1999-10-15
DKPA199901734 1999-12-03
DKPA199901735 1999-12-03
DKPA199901735 1999-12-03
DKPA199901734 1999-12-03
DKPA200000522 2000-03-28
DKPA200000522 2000-03-28
DKPA200000671 2000-04-19
DKPA200000671 2000-04-19
DKPA200000670 2000-04-19
DKPA200000670 2000-04-19
US21175800P 2000-06-14 2000-06-14
US21187800P 2000-06-14 2000-06-14
US21143500P 2000-06-14 2000-06-14
US60/211,758 2000-06-14
US60/211,878 2000-06-14
US60/211,435 2000-06-14

Publications (2)

Publication Number Publication Date
WO2001027261A2 WO2001027261A2 (en) 2001-04-19
WO2001027261A3 true WO2001027261A3 (en) 2002-02-28

Family

ID=27582959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000580 Ceased WO2001027261A2 (en) 1998-11-11 2000-10-13 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino

Country Status (8)

Country Link
EP (1) EP1220902A2 (en)
JP (1) JP2003511466A (en)
AU (1) AU7773000A (en)
CA (1) CA2388991A1 (en)
HU (1) HUP0203465A2 (en)
IL (1) IL149095A0 (en)
NO (1) NO20021711L (en)
WO (1) WO2001027261A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248281A1 (en) * 2000-04-06 2001-10-23 Pantheco A/S Pharmaceutical composition of modified pna molecules
WO2002015896A2 (en) * 2000-08-25 2002-02-28 Trustees Of Tufts College Methods and compositions for potentiating antibiotic action against persistent/tolerant pathogenic microorganisms
EP1335933A2 (en) * 2000-11-24 2003-08-20 Pantheco A/S Pna analogues
AU2002216946A1 (en) * 2001-01-05 2002-07-16 Pantheco A/S Modified pna molecules
WO2002079467A2 (en) * 2001-03-29 2002-10-10 Københavns Universitet Antibiotic-free bacterial strain selection with antisense molecules
AU2003223923A1 (en) * 2002-05-01 2003-11-17 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
US20090030257A1 (en) * 2007-07-25 2009-01-29 Ceramoptec Industries Inc. Anti-microbial photodynamic therapy
WO2016055810A1 (en) * 2014-10-09 2016-04-14 University Of Strathclyde Self-assembling tripeptides

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330221A2 (en) * 1988-02-26 1989-08-30 Enzo Biochem, Inc. End labeled nuceotide probe
WO1996002558A1 (en) * 1994-07-15 1996-02-01 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1996038163A1 (en) * 1995-05-31 1996-12-05 Biosynth S.R.L. Compositions containing an antibiotic and a peptide potentiating this antibiotic
WO1998032467A2 (en) * 1997-01-24 1998-07-30 Antivirals, Inc. Method and conjugate for treating h. pylori infection
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO1999007728A2 (en) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330221A2 (en) * 1988-02-26 1989-08-30 Enzo Biochem, Inc. End labeled nuceotide probe
WO1996002558A1 (en) * 1994-07-15 1996-02-01 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1996038163A1 (en) * 1995-05-31 1996-12-05 Biosynth S.R.L. Compositions containing an antibiotic and a peptide potentiating this antibiotic
WO1998032467A2 (en) * 1997-01-24 1998-07-30 Antivirals, Inc. Method and conjugate for treating h. pylori infection
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
WO1999007728A2 (en) * 1997-08-12 1999-02-18 Synt:Em (S.A.) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
WO1999014226A2 (en) * 1997-09-12 1999-03-25 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUFOURCQ, J. ET AL: "Molecular assembling of DNA with amphipathic peptides", FEBS LETT. (1998), 421(1), 7-11, XP002162325 *
GOOD, L. & NIELSEN, P.: "Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA", NATURE BIOTECHNOLOGY., vol. 16, April 1998 (1998-04-01), pages 355 - 358, XP002140166, ISSN: 1087-0156 *
ISHIHARA, TSUTOMU ET AL: "Rules for Strand Invasion by Chemically Modified Oligonucleotides", J. AM. CHEM. SOC. 121(10), 2012-2020, 24 February 1999 (1999-02-24), XP002140165 *
SIMMONS C G ET AL: "Synthesis and membrane permeability of pna-peptide conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 23, 2 December 1997 (1997-12-02), pages 3001 - 3006, XP004136573, ISSN: 0960-894X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression

Also Published As

Publication number Publication date
JP2003511466A (en) 2003-03-25
EP1220902A2 (en) 2002-07-10
NO20021711D0 (en) 2002-04-11
NO20021711L (en) 2002-06-11
IL149095A0 (en) 2002-11-10
WO2001027261A2 (en) 2001-04-19
AU7773000A (en) 2001-04-23
CA2388991A1 (en) 2001-04-19
HUP0203465A2 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
WO2005030259A3 (en) Nucleic acid-lipophilic conjugates
WO2004024757A3 (en) Modified pna molecules
WO2002038738A3 (en) Chimeric molecules to modulate gene expression
IL197339A (en) Recombinant uricase chimeric protein, a conjugate comprising the protein and pharmaceutical compositions comprising the same
AU2001270142A1 (en) Bioengineered vehicles for targeted nucleic acid delivery
WO2002050122A3 (en) Means for the diagnosis and therapy of ctcl
WO2001027261A3 (en) Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
WO2001076636A3 (en) Pharmaceutical composition of modified pna molecules
WO2001010896A3 (en) Factor x analog with an improved ability to be activated
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
CA2316113A1 (en) Method for nucleic acid purification using iodine
WO2001071007A3 (en) GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
CA2340934A1 (en) Novel collectin
AU7381600A (en) Covalently linked dimeric dna binding molecules
AU2001278509A1 (en) Nucleotide sequences which code for the atr43 gene
AU2001291658A1 (en) Nucleotide sequences which code for the ccpa2 gene
AU2001293808A1 (en) Nucleotide sequences which code for the atr61 gene
AU2001287631A1 (en) Nucleotide sequences which code for the metf gene
AU4707700A (en) Sulfohydrolases, corresponding amino acid and nucleotide sequences, sulfohydrolase preparations, processes, and products thereof
AU2001295580A1 (en) Nucleotide sequences which code for the dep67 protein
AU2001293730A1 (en) Nucleotide sequences which code for the chra gene
AU2001282023A1 (en) Nucleotide sequences which code for the def gene
WO2002022807A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
BR0014756A (en) Conjugates between a peptide and a nucleic acid analog, such as a pna, an lna or a morpholino
WO2005060573A3 (en) Pna-neamine conjugates and methods for producing and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002/02455

Country of ref document: ZA

Ref document number: 200202455

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 77730/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00423/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000967618

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 149095

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2388991

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 530466

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008152810

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2002 2002109476

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000967618

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000967618

Country of ref document: EP